These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35462030)

  • 1. The HER family as therapeutic targets in colorectal cancer.
    Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
    Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of human epidermal growth factor receptor family in pulmonary lymphangioleiomyomatosis.
    Kobayashi K; Miki Y; Saito R; Adachi K; Seyama K; Okada Y; Sasano H
    Hum Pathol; 2018 Nov; 81():121-130. PubMed ID: 30030119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
    Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
    Pereira PMR; Abma L; Henry KE; Lewis JS
    Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
    Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
    Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
    Hsieh AC; Moasser MM
    Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
    Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
    Claus J; Patel G; Ng T; Parker PJ
    Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
    Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
    PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
    Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II
    Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
    Nakata S; Tanaka H; Ito Y; Hara M; Fujita M; Kondo E; Kanemitsu Y; Yatabe Y; Nakanishi H
    Int J Oncol; 2014 Oct; 45(4):1583-93. PubMed ID: 25017791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.